GlobeNewswire·Jun 5, 2026, 4:01 PM ET

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jade Biosciences, Inc. closed its public offering of 11,500,000 common stock shares, including 1,500,000 shares from the full exercise of the underwriters' option.
The shares were sold to the public at $15.00 per share, generating $172.5 million in gross proceeds before deducting underwriting discounts, commissions, & other expenses.
All shares sold in the offering were issued directly by Jade Biosciences.
Net proceeds will fund clinical trials, preclinical studies, manufacturing, research & development, capital expenditures, working capital, & other general corporate purposes.
Jefferies, TD Cowen, & UBS Investment Bank served as joint book-running managers; LifeSci Capital acted as passive book-running manager; BTIG served as lead manager.
The offering was executed under a shelf registration statement on Form S-3 declared effective by the SEC on May 15, 2026.
Jade Biosciences is a clinical-stage biotechnology company developing therapies for autoimmune diseases, with lead candidate JADE101 targeting the cytokine APRIL for immunoglobulin A nephropathy treatment.